BridgeMD
Stopstudy
EU CTIS ID: 2023-505143-39-00
What this study is testing
Explore changes in cardiovascular risk determinants after stopping estradiol therapy in older long-term gender-affirming hormone therapy (GHT) receiving transgender women for 12 weeks and after restarting estradiol therapy again for 12 weeks.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age > 54 years
- Use of gender-affirming hormone therapy (GHT) for at least 10 years
- Current use of GHT
- Currently in treatment at the Center of Expertise on Gender Dysphoria: last clinical appointment <3 years ago
- Undergone gonadectomy (i.e., vaginoplasty or orchiectomy)
You likely can't join if
- Insufficient understanding of the Dutch language
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.